0 XP   0   0   0

Immunoprecise Antibodies Ltd










Financial Health of Immunoprecise Antibodies Ltd




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Immunoprecise Antibodies Ltd
Buy, Hold or Sell?

Should you buy, hold or sell Immunoprecise Antibodies Ltd?

I guess you are interested in Immunoprecise Antibodies Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Immunoprecise Antibodies Ltd

Let's start. I'm going to help you getting a better view of Immunoprecise Antibodies Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Immunoprecise Antibodies Ltd even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Immunoprecise Antibodies Ltd is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Immunoprecise Antibodies Ltd. The closing price on 2022-11-25 was C$6.5 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Immunoprecise Antibodies Ltd Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Immunoprecise Antibodies Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immunoprecise Antibodies Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -200.1% means that $-2.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immunoprecise Antibodies Ltd:

  • The MRQ is -200.1%. The company is making a huge loss. -2
  • The TTM is -118.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-200.1%TTM-118.6%-81.5%
TTM-118.6%YOY-53.0%-65.6%
TTM-118.6%5Y-70.0%-48.6%
5Y-70.0%10Y-113.7%+43.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-200.1%-223.6%+23.5%
TTM-118.6%-281.7%+163.1%
YOY-53.0%-344.8%+291.8%
5Y-70.0%-450.1%+380.1%
10Y-113.7%-541.0%+427.3%
1.1.2. Return on Assets

Shows how efficient Immunoprecise Antibodies Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • -11.7% Return on Assets means that Immunoprecise Antibodies Ltd generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immunoprecise Antibodies Ltd:

  • The MRQ is -11.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.7%TTM-7.9%-3.8%
TTM-7.9%YOY-4.1%-3.8%
TTM-7.9%5Y-6.0%-1.9%
5Y-6.0%10Y-12.0%+6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.7%-9.9%-1.8%
TTM-7.9%-8.9%+1.0%
YOY-4.1%-9.3%+5.2%
5Y-6.0%-11.7%+5.7%
10Y-12.0%-12.7%+0.7%
1.1.3. Return on Equity

Shows how efficient Immunoprecise Antibodies Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • -14.2% Return on Equity means Immunoprecise Antibodies Ltd generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immunoprecise Antibodies Ltd:

  • The MRQ is -14.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.2%TTM-9.5%-4.6%
TTM-9.5%YOY-5.0%-4.5%
TTM-9.5%5Y-8.8%-0.8%
5Y-8.8%10Y-15.8%+7.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.2%-12.0%-2.2%
TTM-9.5%-11.5%+2.0%
YOY-5.0%-10.8%+5.8%
5Y-8.8%-14.2%+5.4%
10Y-15.8%-15.2%-0.6%

1.2. Operating Efficiency of Immunoprecise Antibodies Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immunoprecise Antibodies Ltd is operating .

  • Measures how much profit Immunoprecise Antibodies Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • An Operating Margin of -213.6% means the company generated $-2.14  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immunoprecise Antibodies Ltd:

  • The MRQ is -213.6%. The company is operating very inefficient. -2
  • The TTM is -118.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-213.6%TTM-118.9%-94.7%
TTM-118.9%YOY-49.1%-69.8%
TTM-118.9%5Y-57.7%-61.2%
5Y-57.7%10Y-62.5%+4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-213.6%-207.3%-6.3%
TTM-118.9%-271.0%+152.1%
YOY-49.1%-325.9%+276.8%
5Y-57.7%-454.0%+396.3%
10Y-62.5%-537.1%+474.6%
1.2.2. Operating Ratio

Measures how efficient Immunoprecise Antibodies Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.55 means that the operating costs are $3.55 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immunoprecise Antibodies Ltd:

  • The MRQ is 3.550. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.610. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.550TTM2.610+0.939
TTM2.610YOY1.775+0.835
TTM2.6105Y2.025+0.585
5Y2.02510Y2.034-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5502.871+0.679
TTM2.6103.504-0.894
YOY1.7753.604-1.829
5Y2.0255.132-3.107
10Y2.0346.371-4.337

1.3. Liquidity of Immunoprecise Antibodies Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immunoprecise Antibodies Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.06 means the company has $5.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immunoprecise Antibodies Ltd:

  • The MRQ is 5.058. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.155. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.058TTM5.155-0.097
TTM5.155YOY5.392-0.237
TTM5.1555Y3.439+1.716
5Y3.43910Y3.620-0.181
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0585.117-0.059
TTM5.1555.755-0.600
YOY5.3925.854-0.462
5Y3.4396.511-3.072
10Y3.6206.222-2.602
1.3.2. Quick Ratio

Measures if Immunoprecise Antibodies Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.70 means the company can pay off $0.70 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immunoprecise Antibodies Ltd:

  • The MRQ is 0.696. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.483. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.696TTM0.483+0.213
TTM0.483YOY0.652-0.169
TTM0.4835Y0.634-0.151
5Y0.63410Y0.683-0.049
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6964.284-3.588
TTM0.4834.664-4.181
YOY0.6524.787-4.135
5Y0.6345.218-4.584
10Y0.6835.182-4.499

1.4. Solvency of Immunoprecise Antibodies Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immunoprecise Antibodies Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immunoprecise Antibodies Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Immunoprecise Antibodies Ltd assets are financed with 17.1% credit (debt) and the remaining percentage (100% - 17.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immunoprecise Antibodies Ltd:

  • The MRQ is 0.171. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.169. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.171TTM0.169+0.002
TTM0.169YOY0.210-0.040
TTM0.1695Y0.305-0.135
5Y0.30510Y0.289+0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1710.278-0.107
TTM0.1690.277-0.108
YOY0.2100.306-0.096
5Y0.3050.367-0.062
10Y0.2890.403-0.114
1.4.2. Debt to Equity Ratio

Measures if Immunoprecise Antibodies Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 20.7% means that company has $0.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immunoprecise Antibodies Ltd:

  • The MRQ is 0.207. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.204. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.207TTM0.204+0.002
TTM0.204YOY0.274-0.070
TTM0.2045Y0.485-0.281
5Y0.48510Y0.452+0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2070.315-0.108
TTM0.2040.317-0.113
YOY0.2740.319-0.045
5Y0.4850.403+0.082
10Y0.4520.462-0.010

2. Market Valuation of Immunoprecise Antibodies Ltd

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Immunoprecise Antibodies Ltd generates.

  • Above 15 is considered overpriced but always compare Immunoprecise Antibodies Ltd to the Biotechnology industry mean.
  • A PE ratio of -14.01 means the investor is paying $-14.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immunoprecise Antibodies Ltd:

  • The EOD is -17.209. Company is losing money. -2
  • The MRQ is -14.006. Company is losing money. -2
  • The TTM is -36.178. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-17.209MRQ-14.006-3.204
MRQ-14.006TTM-36.178+22.172
TTM-36.178YOY-273.917+237.739
TTM-36.1785Y-168.098+131.920
5Y-168.09810Y-165.775-2.323
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.209-8.986-8.223
MRQ-14.006-9.792-4.214
TTM-36.178-16.243-19.935
YOY-273.917-20.876-253.041
5Y-168.098-16.665-151.433
10Y-165.775-14.732-151.043
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Immunoprecise Antibodies Ltd.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Immunoprecise Antibodies Ltd:

  • The MRQ is 27.736. Seems overpriced? -1
  • The TTM is 49.502. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ27.736TTM49.502-21.766
TTM49.502YOY-604.225+653.726
TTM49.5025Y3,351,293.089-3,351,243.587
5Y3,351,293.08910Y3,046,598.611+304,694.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.736-0.032+27.768
TTM49.5020.004+49.498
YOY-604.2250.016-604.241
5Y3,351,293.0890.006+3,351,293.083
10Y3,046,598.6110.003+3,046,598.608

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immunoprecise Antibodies Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.98 means the investor is paying $1.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immunoprecise Antibodies Ltd:

  • The EOD is 2.437. Good. +1
  • The MRQ is 1.983. Good. +1
  • The TTM is 3.121. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD2.437MRQ1.983+0.454
MRQ1.983TTM3.121-1.137
TTM3.121YOY8.472-5.351
TTM3.1215Y10.792-7.672
5Y10.79210Y16.743-5.950
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4371.835+0.602
MRQ1.9832.006-0.023
TTM3.1212.774+0.347
YOY8.4723.453+5.019
5Y10.7922.713+8.079
10Y16.7432.402+14.341
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Immunoprecise Antibodies Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3640.109-435%0.358-202%0.130-380%0.116-414%
Book Value Growth--0.1540.269-43%0.405-62%0.333-54%0.309-50%
Book Value Per Share--2.6672.417+10%1.769+51%1.052+154%0.928+187%
Book Value Per Share Growth---0.1370.018-843%0.201-168%0.081-268%0.020-770%
Current Ratio--5.0585.155-2%5.392-6%3.439+47%3.620+40%
Debt To Asset Ratio--0.1710.169+1%0.210-18%0.305-44%0.289-41%
Debt To Equity Ratio--0.2070.204+1%0.274-25%0.485-57%0.452-54%
Dividend Per Share----0%-0%-0%-0%
Eps---0.378-0.230-39%-0.101-73%-0.084-78%-0.083-78%
Eps Growth---0.505-0.182-64%-0.160-68%0.076-767%0.303-266%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---2.001-1.186-41%-0.530-74%-0.700-65%-1.137-43%
Operating Margin---2.136-1.189-44%-0.491-77%-0.577-73%-0.625-71%
Operating Ratio--3.5502.610+36%1.775+100%2.025+75%2.034+75%
Pb Ratio2.437+19%1.9833.121-36%8.472-77%10.792-82%16.743-88%
Pe Ratio-17.209-23%-14.006-36.178+158%-273.917+1856%-168.098+1100%-165.775+1084%
Peg Ratio--27.73649.502-44%-604.225+2278%3351293.089-100%3046598.611-100%
Price Per Share6.500+19%5.2907.160-26%13.078-60%6.525-19%6.223-15%
Price To Total Gains Ratio-17.850-23%-14.527-28.401+96%87.550-117%12.328-218%-7.703-47%
Profit Growth---63.129-39.058-38%-37.467-41%-21.342-66%-11.216-82%
Quick Ratio--0.6960.483+44%0.652+7%0.634+10%0.683+2%
Return On Assets---0.117-0.079-32%-0.041-65%-0.060-49%-0.120+2%
Return On Equity---0.142-0.095-33%-0.050-64%-0.088-38%-0.158+12%
Revenue Growth--0.1680.257-35%0.286-41%0.315-47%0.314-47%
Total Gains Per Share---0.3640.109-435%0.358-202%0.130-380%0.116-414%
Total Gains Per Share Growth---4.051-0.799-80%-6.131+51%-2.390-41%-2.151-47%
Usd Book Value--49336296.80044709226.800+10%32715133.318+51%22337878.228+121%19728388.886+150%
Usd Book Value Change Per Share---0.2710.081-435%0.266-202%0.097-380%0.086-414%
Usd Book Value Per Share--1.9861.800+10%1.317+51%0.784+154%0.691+187%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.281-0.171-39%-0.075-73%-0.063-78%-0.062-78%
Usd Price Per Share4.841+19%3.9405.333-26%9.740-60%4.860-19%4.635-15%
Usd Profit---6986968.800-4256532.000-39%-1865850.988-73%-1873476.027-73%-1839329.551-74%
Usd Revenue--3492367.2003624383.000-4%3488461.283+0%2673812.859+31%2379986.607+47%
Usd Total Gains Per Share---0.2710.081-435%0.266-202%0.097-380%0.086-414%
 EOD+2 -3MRQTTM+8 -24YOY+10 -225Y+11 -2110Y+13 -19

3.2. Fundamental Score

Let's check the fundamental score of Immunoprecise Antibodies Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-17.209
Price to Book Ratio (EOD)Between0-12.437
Net Profit Margin (MRQ)Greater than0-2.001
Operating Margin (MRQ)Greater than0-2.136
Quick Ratio (MRQ)Greater than10.696
Current Ratio (MRQ)Greater than15.058
Debt to Asset Ratio (MRQ)Less than10.171
Debt to Equity Ratio (MRQ)Less than10.207
Return on Equity (MRQ)Greater than0.15-0.142
Return on Assets (MRQ)Greater than0.05-0.117
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Immunoprecise Antibodies Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.824
Ma 20Greater thanMa 506.672
Ma 50Greater thanMa 1006.567
Ma 100Greater thanMa 2006.411
OpenGreater thanClose6.190
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-07-312021-10-312022-01-312022-04-302022-07-31
Tax Provision  18821901820867275-678-403
Income Tax Expense  18821901820867275-678-403



Latest Balance Sheet

Balance Sheet of 2022-07-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets79,944
Total Liabilities13,703
Total Stockholder Equity66,241
 As reported
Total Liabilities 13,703
Total Stockholder Equity+ 66,241
Total Assets = 79,944

Assets

Total Assets79,944
Total Current Assets27,085
Long-term Assets27,085
Total Current Assets
Cash And Cash Equivalents 19,243
Net Receivables 3,729
Inventory 1,549
Total Current Assets  (as reported)27,085
Total Current Assets  (calculated)24,521
+/- 2,564
Long-term Assets
Property Plant Equipment 3,109
Goodwill 19,011
Long Term Investments 137
Intangible Assets 30,153
Other Assets 473
Long-term Assets  (as reported)52,859
Long-term Assets  (calculated)52,883
+/- 24

Liabilities & Shareholders' Equity

Total Current Liabilities5,355
Long-term Liabilities8,348
Total Stockholder Equity66,241
Total Current Liabilities
Accounts payable 1,650
Other Current Liabilities 2,259
Total Current Liabilities  (as reported)5,355
Total Current Liabilities  (calculated)3,909
+/- 1,446
Long-term Liabilities
Other Liabilities 8,040
Deferred Long Term Liability 24
Long-term Liabilities  (as reported)8,348
Long-term Liabilities  (calculated)8,064
+/- 284
Total Stockholder Equity
Common Stock116,183
Retained Earnings -55,909
Total Stockholder Equity (as reported)66,241
Total Stockholder Equity (calculated)60,274
+/- 5,967
Other
Capital Stock116,183
Common Stock Shares Outstanding 24,837
Net Invested Capital 66,241
Net Tangible Assets 17,101
Net Working Capital 21,730



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-10-312017-07-312017-04-302017-01-31
> Total Assets 
4,576
3,929
3,008
13,254
13,082
24,575
23,886
31,048
28,945
28,346
27,867
26,369
25,560
27,263
33,421
43,702
43,600
66,959
64,437
60,328
56,448
93,494
79,944
79,94493,49456,44860,32864,43766,95943,60043,70233,42127,26325,56026,36927,86728,34628,94531,04823,88624,57513,08213,2543,0083,9294,576
   > Total Current Assets 
3,990
3,284
2,215
3,886
3,610
4,783
4,625
11,918
9,621
9,878
8,868
7,816
7,595
7,699
12,995
23,996
24,486
48,858
46,825
43,941
40,559
37,470
27,085
27,08537,47040,55943,94146,82548,85824,48623,99612,9957,6997,5957,8168,8689,8789,62111,9184,6254,7833,6103,8862,2153,2843,990
       Cash And Cash Equivalents 
3,323
2,578
1,270
2,257
1,838
1,806
2,361
8,831
7,123
5,472
4,952
2,964
1,939
2,606
6,062
16,841
15,720
41,759
40,700
38,360
32,986
29,965
19,243
19,24329,96532,98638,36040,70041,75915,72016,8416,0622,6061,9392,9644,9525,4727,1238,8312,3611,8061,8382,2571,2702,5783,323
       Short-term Investments 
157
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000157
       Net Receivables 
453
531
764
1,457
1,433
2,221
1,564
2,443
1,151
1,558
1,341
2,300
2,901
3,749
5,468
5,454
5,069
4,119
3,535
2,900
3,455
3,409
3,729
3,7293,4093,4552,9003,5354,1195,0695,4545,4683,7492,9012,3001,3411,5581,1512,4431,5642,2211,4331,457764531453
       Other Current Assets 
0
0
0
0
19
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000190000
   > Long-term Assets 
0
0
0
0
0
0
0
0
9,075
18,468
18,999
18,553
17,965
19,564
20,426
19,707
19,114
18,101
17,612
16,387
15,889
56,024
52,859
52,85956,02415,88916,38717,61218,10119,11419,70720,42619,56417,96518,55318,99918,4689,07500000000
       Property Plant Equipment 
268
645
779
931
1,036
1,577
1,473
1,717
1,723
1,557
3,018
2,885
2,630
3,063
3,638
3,594
3,565
4,017
4,051
3,638
3,569
3,338
3,109
3,1093,3383,5693,6384,0514,0173,5653,5943,6383,0632,6302,8853,0181,5571,7231,7171,4731,5771,036931779645268
       Goodwill 
0
0
0
4,354
4,354
4,892
4,807
4,692
4,752
8,254
8,019
8,044
8,013
7,909
8,333
8,130
8,120
7,777
7,752
7,501
7,450
19,703
19,011
19,01119,7037,4507,5017,7527,7778,1208,1308,3337,9098,0138,0448,0198,2544,7524,6924,8074,8924,3544,354000
       Long Term Investments 
0
0
0
90
90
90
85
85
85
90
90
90
90
119
127
116
116
111
110
106
105
142
137
13714210510611011111611612711990909090858585909090000
       Intangible Assets 
0
0
1
3,992
3,991
4,047
3,870
3,675
3,616
8,417
7,777
7,471
7,148
8,285
8,230
7,758
7,209
6,058
5,531
4,862
4,522
32,390
30,153
30,15332,3904,5224,8625,5316,0587,2097,7588,2308,2857,1487,4717,7778,4173,6163,6753,8704,0473,9913,992100
       Long-term Assets Other 
0
0
0
0
0
0
0
0
19,324
67
37
26
66
85
84
84
81
79
80
79
81
82
81
818281798079818484856626376719,32400000000
> Total Liabilities 
743
837
541
2,659
2,938
11,872
11,637
10,404
9,083
10,277
12,165
11,766
11,111
12,177
13,505
12,625
11,341
10,035
8,999
9,428
8,760
18,209
13,703
13,70318,2098,7609,4288,99910,03511,34112,62513,50512,17711,11111,76612,16510,2779,08310,40411,63711,8722,9382,659541837743
   > Total Current Liabilities 
617
837
541
511
1,545
4,284
4,073
3,730
2,624
7,204
7,454
7,013
6,455
7,930
7,599
7,843
7,232
6,072
6,616
7,526
7,142
9,263
5,355
5,3559,2637,1427,5266,6166,0727,2327,8437,5997,9306,4557,0137,4547,2042,6243,7304,0734,2841,545511541837617
       Short-term Debt 
92
0
0
0
0
188
357
127
101
2,791
2,881
2,806
2,795
0
0
0
0
0
0
0
0
0
0
00000000002,7952,8062,8812,791101127357188000092
       Short Long Term Debt 
92
0
0
0
0
188
357
127
101
2,791
2,881
2,806
2,795
2,122
107
7
0
0
1,342
1,271
1,292
1,312
0
01,3121,2921,2711,3420071072,1222,7952,8062,8812,791101127357188000092
       Accounts payable 
332
650
277
175
443
2,038
1,744
1,525
887
1,594
1,275
1,083
970
1,354
1,727
1,389
1,794
1,816
2,544
3,173
2,297
3,468
1,650
1,6503,4682,2973,1732,5441,8161,7941,3891,7271,3549701,0831,2751,5948871,5251,7442,038443175277650332
       Other Current Liabilities 
191
172
250
331
1,100
2,055
1,965
2,075
1,628
2,783
2,956
2,782
2,225
3,290
4,476
4,732
3,309
1,935
1,313
1,700
1,571
2,262
2,259
2,2592,2621,5711,7001,3131,9353,3094,7324,4763,2902,2252,7822,9562,7831,6282,0751,9652,0551,100331250172191
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
6,459
3,072
4,711
4,753
4,656
4,248
5,906
4,782
4,109
3,963
2,383
1,902
1,618
8,946
8,348
8,3488,9461,6181,9022,3833,9634,1094,7825,9064,2484,6564,7534,7113,0726,45900000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
107
1,725
1,627
1,361
1,884
2,387
2,194
1,936
1,926
1,947
1,658
1,522
1,234
1,124
1,1241,2341,5221,6581,9471,9261,9362,1942,3871,8841,3611,6271,725107000000000
       Deferred Long Term Liability 
0
0
13
0
0
0
0
0
0
0
10
71
166
115
140
396
386
32
30
29
27
25
24
242527293032386396140115166711000000001300
> Total Stockholder Equity
3,833
3,092
2,467
10,594
10,145
12,703
12,249
20,644
19,862
18,069
15,702
14,604
14,449
15,086
19,916
31,078
32,259
56,924
55,438
50,900
47,688
75,285
66,241
66,24175,28547,68850,90055,43856,92432,25931,07819,91615,08614,44914,60415,70218,06919,86220,64412,24912,70310,14510,5942,4673,0923,833
   Common Stock
7,142
7,460
7,460
16,167
16,431
20,455
21,202
31,236
31,272
32,699
32,726
32,728
32,728
34,087
38,402
50,454
52,226
80,102
80,876
81,486
81,790
114,559
116,183
116,183114,55981,79081,48680,87680,10252,22650,45438,40234,08732,72832,72832,72632,69931,27231,23621,20220,45516,43116,1677,4607,4607,142
   Retained Earnings -55,909-46,528-41,884-38,058-33,049-29,819-24,786-23,492-23,028-22,479-21,533-20,907-19,543-17,476-13,634-12,447-10,839-9,737-7,539-6,327-5,424-4,566-3,369
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
8
0
74
44
89
277
-108
-322
-189
-228
-829
-780
-451
-300
819
356
306
-560
-691
-1,319
-1,383
-2,376
-4,336
-4,336-2,376-1,383-1,319-691-560306356819-300-451-780-829-228-189-322-10827789447408



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2022-04-30)

Gross Profit (+$)
totalRevenue19,364
Cost of Revenue-8,381
Gross Profit10,98310,983
 
Operating Income (+$)
Gross Profit10,983
Operating Expense-35,534
Operating Income-16,170-24,551
 
Operating Expense (+$)
Research Development6,693
Selling General Administrative17,710
Selling And Marketing Expenses-
Operating Expense35,53424,403
 
Net Interest Income (+$)
Interest Income279
Interest Expense-419
Net Interest Income-140-140
 
Pretax Income (+$)
Operating Income-16,170
Net Interest Income-140
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-15,848-16,632
EBIT - interestExpense = -16,654
-15,848
-16,290
Interest Expense419
Earnings Before Interest and Taxes (ebit)-16,235-15,429
Earnings Before Interest and Taxes (ebitda)-11,660
 
After tax Income (+$)
Income Before Tax-15,848
Tax Provision-861
Net Income From Continuing Ops-16,709-16,709
Net Income-16,709
Net Income Applicable To Common Shares-16,709
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net462140
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
WABAG.BSE
2 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of WABAG.BSE.

WABAG.BSE Daily Candlestick Chart
TLGN.PINK
4 minutes ago

I found you a MACD Bearish Hidden Divergence on the daily chart of TLGN.PINK.

TLGN.PINK Daily Candlestick Chart
INDGW.MI
13 minutes ago

I found you a Golden Cross on the daily chart of INDGW.MI.

INDGW.MI Daily Candlestick Chart
IMIB.MI
14 minutes ago

I found you a Golden Cross on the daily chart of IMIB.MI.

IMIB.MI Daily Candlestick Chart
IESE.MI
18 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IESE.MI.

IESE.MI Daily Candlestick Chart
HER.MI
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HER.MI.

HER.MI Daily Candlestick Chart
HEAL.MI
31 minutes ago

I found you a Golden Cross on the daily chart of HEAL.MI.

HEAL.MI Daily Candlestick Chart
H50E.MI
31 minutes ago

I found you a Golden Cross on the daily chart of H50E.MI.

H50E.MI Daily Candlestick Chart
GLUG.MI
34 minutes ago

I found you a Golden Cross on the daily chart of GLUG.MI.

GLUG.MI Daily Candlestick Chart
JPASSOCIAT.NSE
39 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JPASSOCIAT.NSE.

JPASSOCIAT.NSE Daily Candlestick Chart
GREENPOWER.NSE
41 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GREENPOWER.NSE.

GREENPOWER.NSE Daily Candlestick Chart
CARERATING.NSE
52 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CARERATING.NSE.

CARERATING.NSE Daily Candlestick Chart
BHANDARI.NSE
55 minutes ago

I found you a Bearish Engulfing Candle Pattern on the daily chart of BHANDARI.NSE.

BHANDARI.NSE Daily Candlestick Chart
BANKA.NSE
56 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of BANKA.NSE.

BANKA.NSE Daily Candlestick Chart
BALRAMCHIN.NSE
57 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BALRAMCHIN.NSE.

BALRAMCHIN.NSE Daily Candlestick Chart
BAJAJHIND.NSE
58 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BAJAJHIND.NSE.

BAJAJHIND.NSE Daily Candlestick Chart
ADFFOODS.NSE
1 hour ago

I found you a Golden Cross on the daily chart of ADFFOODS.NSE.

ADFFOODS.NSE Daily Candlestick Chart
ACCURACY.NSE
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ACCURACY.NSE.

ACCURACY.NSE Daily Candlestick Chart
ACC.NSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ACC.NSE.

ACC.NSE Daily Candlestick Chart
VCL.NSE
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VCL.NSE.

VCL.NSE Daily Candlestick Chart
ASHOKA.NSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASHOKA.NSE.

ASHOKA.NSE Daily Candlestick Chart
APOLLO.NSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of APOLLO.NSE.

APOLLO.NSE Daily Candlestick Chart
WANBURY.NSE
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of WANBURY.NSE.

WANBURY.NSE Daily Candlestick Chart
WABAG.NSE
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of WABAG.NSE.

WABAG.NSE Daily Candlestick Chart
VBL.NSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBL.NSE.

VBL.NSE Daily Candlestick Chart